146 related articles for article (PubMed ID: 38326481)
1. Development of a whole spinal MRI-based tumor burden scoring method in participants with multiple myeloma: a pilot study of prognostic significance.
Cui S; Guo Y; Li J; Bian W; Wu W; Zhang W; Zheng Q; Guan H; Wang J; Niu J
Ann Hematol; 2024 May; 103(5):1665-1673. PubMed ID: 38326481
[TBL] [Abstract][Full Text] [Related]
2. The quantitative parameters based on marrow metabolism derived from synthetic MRI: A pilot study of prognostic value in participants with newly diagnosed multiple myeloma.
Cui S; Guo Y; Niu W; Li J; Bian W; Wu W; Zhang W; Zheng Q; Wang J; Niu J
Cancer Med; 2024 Apr; 13(7):e7109. PubMed ID: 38553942
[TBL] [Abstract][Full Text] [Related]
3. [Application of the Second Revision of the International Staging System (R2-ISS) in the prognostic assessment of newly diagnosed multiple myeloma].
Yan J; Zhou DM; Shao XY; Xu Y; Chen B
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):170-177. PubMed ID: 38604794
[No Abstract] [Full Text] [Related]
4. Development of a Semiquantitative Whole-Body MRI Scoring System for Multiple Myeloma.
Kim DK; Jung JY; Kim H; Lee S; Lee SY; Lee S; Park SS; Min CK
Radiology; 2023 Sep; 308(3):e230667. PubMed ID: 37668524
[TBL] [Abstract][Full Text] [Related]
5. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
D'Agostino M; Cairns DA; Lahuerta JJ; Wester R; Bertsch U; Waage A; Zamagni E; Mateos MV; Dall'Olio D; van de Donk NWCJ; Jackson G; Rocchi S; Salwender H; Bladé Creixenti J; van der Holt B; Castellani G; Bonello F; Capra A; Mai EK; Dürig J; Gay F; Zweegman S; Cavo M; Kaiser MF; Goldschmidt H; Hernández Rivas JM; Larocca A; Cook G; San-Miguel JF; Boccadoro M; Sonneveld P
J Clin Oncol; 2022 Oct; 40(29):3406-3418. PubMed ID: 35605179
[TBL] [Abstract][Full Text] [Related]
6. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
Gopalakrishnan S; D'Souza A; Scott E; Fraser R; Davila O; Shah N; Gale RP; Kamble R; Diaz MA; Lazarus HM; Savani BN; Hildebrandt GC; Solh M; Freytes CO; Lee C; Kyle RA; Usmani SZ; Ganguly S; Assal A; Berdeja J; Kanate AS; Dhakal B; Meehan K; Kindwall-Keller T; Saad A; Locke F; Seo S; Nishihori T; Gergis U; Gasparetto C; Mark T; Nieto Y; Kumar S; Hari P
Biol Blood Marrow Transplant; 2019 Apr; 25(4):683-688. PubMed ID: 30579965
[TBL] [Abstract][Full Text] [Related]
7. Histogram Analysis Based on Apparent Diffusion Coefficient Maps of Bone Marrow in Multiple Myeloma: An Independent Predictor for High-risk Patients Classified by the Revised International Staging System.
Wang Q; Zhang L; Li S; Sun Z; Wu X; Zhao A; Benkert T; Zhou D; Xue H; Jin Z; Li J
Acad Radiol; 2022 Jun; 29(6):e98-e107. PubMed ID: 34452820
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].
Zhou HX; Jian Y; Du J; Liu JR; Zhang ZY; Geng CY; Yang GZ; Wang GR; Fu WJ; Li J; Chen WM; Gao W
Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):81-88. PubMed ID: 38186122
[No Abstract] [Full Text] [Related]
9. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma.
Dutoit JC; Vanderkerken MA; Verstraete KL
Eur J Radiol; 2013 Sep; 82(9):1444-52. PubMed ID: 23726124
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
Shang Y; Jin Y; Liu H; Ding L; Tong X; Tu H; Zang L; Lin C; Hu J; Zhou F
Hematol Oncol; 2022 Apr; 40(2):212-222. PubMed ID: 34860428
[TBL] [Abstract][Full Text] [Related]
11. [Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma].
Chen HM; Wei W; Peng R; Shi HT; Chen XL; Wu LX; Zhou N; Zhou F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):110-114. PubMed ID: 30738456
[TBL] [Abstract][Full Text] [Related]
12.
Jung SH; Kwon SY; Min JJ; Bom HS; Ahn SY; Jung SY; Lee SS; Park MR; Yang DH; Ahn JS; Kim HJ; Lee JJ
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):107-115. PubMed ID: 30187105
[TBL] [Abstract][Full Text] [Related]
13. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
Bila J; Jelicic J; Dencic Fekete M; Trajkovic G; Sretenovic A; Perunicic Jovanovic M; Antic D; Mihaljevic B
Oncol Res Treat; 2017; 40(10):616-620. PubMed ID: 28950269
[TBL] [Abstract][Full Text] [Related]
14. Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients.
Al Saleh AS; Parmar HV; Visram A; Muchtar E; Buadi FK; Go RS; Dispenzieri A; Kapoor P; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kourelis TV; Gertz MA; Kyle RA; Rajkumar SV; Kumar SK
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):596-601. PubMed ID: 32360276
[TBL] [Abstract][Full Text] [Related]
15. Spinal metastases in multiple myeloma: A high-risk subgroup for ISS III patients.
Cossu G; Terrier LM; Benboubker L; Destrieux C; Velut S; François P; Zemmoura I; Amelot A
Surg Oncol; 2018 Jun; 27(2):321-326. PubMed ID: 29937188
[TBL] [Abstract][Full Text] [Related]
16. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.
Mai EK; Hielscher T; Kloth JK; Merz M; Shah S; Raab MS; Hillengass M; Wagner B; Jauch A; Hose D; Weber MA; Delorme S; Goldschmidt H; Hillengass J
Haematologica; 2015 Jun; 100(6):818-25. PubMed ID: 25795721
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R
Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394
[TBL] [Abstract][Full Text] [Related]
18. Prognostic evaluation and staging optimization of the Mayo Additive Staging System (MASS) in real world for newly diagnosed multiple myeloma patients.
Cao Y; Gong Y; Zhou X; Sun C
Hematology; 2023 Dec; 28(1):2208914. PubMed ID: 37145015
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors].
Wang XX; Zhang LL; Wang T; Hou JX; Wang ZT; Qin H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):777-782. PubMed ID: 37356939
[TBL] [Abstract][Full Text] [Related]
20. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.
Scott EC; Hari P; Kumar S; Fraser R; Davila O; Shah N; Gale RP; Diaz MA; Agrawal V; Cornell RF; Ganguly S; Akpek G; Freytes C; Hashmi S; Malek E; Kamble RT; Lazarus H; Solh M; Usmani SZ; Kanate AS; Saad A; Chhabra S; Gergis U; Cerny J; Kyle RA; Lee C; Kindwall-Keller T; Assal A; Hildebrandt GC; Holmberg L; Maziarz RT; Nishihori T; Seo S; Kumar S; Mark T; D'Souza A
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2443-2449. PubMed ID: 30142419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
